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Available online 8 December 2015Loss-of-functionmutations inDOCK8 are linked to hyper-IgE syndrome. Patients typically presentwith recurrent
sinopulmonary infections, severe cutaneous viral infections, food allergies and elevated serum IgE. Although pa-
tients may present with a spectrum of disease-related symptoms, molecular mechanisms explaining phenotypic
variability in patients are poorly deﬁned. Here we characterized a novel compound heterozygous mutation in
DOCK8 in a patient diagnosed with primary combined immunodeﬁciency which was not typical of classical
DOCK8 deﬁciency. In contrast to previously identiﬁedmutations inDOCK8which result in complete loss of func-
tion, the newly identiﬁed single nucleotide insertion results in expression of a truncated DOCK8 protein. Func-
tional evaluation of the truncated DOCK8 protein revealed its hypomorphic function. In addition we found
somatic reversion of DOCK8 predominantly in T cells. The combination of somatic reversion and hypomorphic
DOCK8 function explains the milder and atypical phenotype of the patient and further broadens the spectrum
of DOCK8-associated disease.







Bi-allelic loss-of-function mutations in the guanine-nucleotide
exchange factor dedicator of cytokinesis 8 (DOCK8) cause autosomal
recessive hyper-IgE syndrome. The vast majority of DOCK8-deﬁcient
patients presentwith combined immunodeﬁciency characterized by re-
current sino-pulmonary and/or gastrointestinal infections, severe cuta-
neous viral infections, severe atopy, eosinophilia andmassively elevated
serum IgE levels. Patients also have a predisposition to cancer [1,2].cinimidyl ester; DHR1/2, DOCK
EBV, Epstein–Barr-Virus; HC,
erring to c.6019dupT); PBMC,
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xperimental Medicine and BRC
ospital, Level 7, Room 7400,
A.-K. Kienzler).
. This is an open access article underRecent studies have highlighted the phenotypic variability of pa-
tients suffering from DOCK8-deﬁciency [3,4]. Patients with susceptibili-
ty to infection but less severe allergic disease were identiﬁed to carry a
functional wild-type DOCK8 allele in lymphocyte subpopulations due to
somatic reversion of the mutated DOCK8 alleles [3].
Here we report for the ﬁrst time a patient with a hypomorphic
mutation in DOCK8 presenting with recurrent bacterial infections, low
serum IgM and IgG, CD4 lymphopenia and severely impaired vaccina-
tion responses, but without severe viral infections and severe atopy.2. Methods
Detailed information can be found in the Supplementary data.
We submitted the variants identiﬁed in DOCK8 to bemade publical-
ly available by ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/). The ac-
cession numbers are SCV000257461 (deletion chr9:204193-343954),
SCV000257462 (c.65CNT), SCV000257463 (c.289CNA), SCV000257464
(c4107CNG), SCV000257465 (c.5433GNA), and SCV000257466
(c.6019dupT).the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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The female patient is the only child of non-consanguineous, healthy
parents. She presented aged eight with a two-year history of recurrent
bacterial chest infections and radiological signs of early bronchiectasis.
The patient also had a long-standing history of mild eczema and asthma
requiring treatment with inhaled corticosteroids and beta-agonists. All
routine childhood immunizations were received uneventfully. Im-
munological evaluation (Table 1) revealed low serum IgM, normal IgA
and IgE, and borderline-low IgG levels which dropped signiﬁcantly
over 12 months. Measurement of responses to previous immunizations
demonstrated protective levels of IgG to tetanus toxoid but absent IgG
to Haemophilus inﬂuenzae type b, pneumococcal polysaccharides and
measles. Also, despite a history of a normal course of chicken-pox,
varicella zoster virus IgGwas undetectable. Lymphocyte subset analysis
demonstrated low CD4+ T cell numbers and low frequencies of CD27+
effector B cells (Table 1). Following the failure of antibiotic prophylaxis
alone to reduce the infection burden, immunoglobulin replacement
therapy was commenced with a good clinical response. Sequence anal-
ysis of recombination-activating gene (RAG) 1, RAG2, and DNA cross-
link repair 1C (DCLRE1C encoding Artemis) did not reveal any muta-
tions. Therefore the patient was given a diagnosis of undeﬁned primary
combined immunodeﬁciency.Table 1
Immunological characteristics of the patient.
Parameter Patient Normal range
Serum immunoglobulin
IgM (g/L) ↓ 0.23 0.4–2.5
IgG (g/L) N/(↓)a 7.04 6.0–13.0
IgA (g/L) N 2.75 0.8–3.0
IgEb (kU/L) N 190 b380
Leukocyte count (no./μL) and phenotype (%)
Lymphocytes (/μL) N 1170 1000–5300
CD19+ B cells
CD19+ (/μL) N 530 200–600
CD38++IgM++ transitional (%) ↑ 14.2 4.6–8.3c
CD27− IgD+ naive (%) ↑ 91 47.3–77.0c
CD27+IgD+ natural effector (%) ↓ 3.44 5.2–20.4c
CD27+IgD− switched memory (%) ↓ 1.12 10.9–30.4c
CD3+ T cells
CD3+ (/μL) ↓ 570 800–3500
CD4+ (/μL) ↓ 180 400–2100
CD4+CD45RA+ naïve (%) ↓ 39 46–77d
CD4+CD45RO+ memory (%) ↑ 61.1 13–30d
CD4+CD45RA+CD31+ RTE (%) ↓ 32.5 42–74d
CD8+ (/μL) N 280 200–1200
CD8+CD45RA+ naïve (%) ↓ 41.4 63–92d
CD8+ CD45RO+ memory (%) ↑ 58.6 4–21d
CD16+CD56+ NK cells (/μL) N 80 70–1200
Eosinophils (/μL) ↑ 1150 b350
TRECs (/106 MNC) ↓ 1197 N10,000
Speciﬁc IgG responses
Tetanus toxoid (IU/ml) N 0.03 N0.01
Haemophilus inﬂuenzae type b (μg/ml) ↓ b0.15 0.15–1.0




PHA ↓↓ absent at 10 years of age
↓ decreased at 15 years of age
N, value within normal range; ↑, value above normal range; ↓, value below normal range;
RTE, recent thymic emigrants; TREC, T cell receptor rearrangement excision circle; PHA,
phytohemagglutinin.
a Serum IgG dropped within a year after initial presentation.
b Serum IgE was measured after identiﬁcation of the DOCK8 mutation on serum sam-
ples frozen before start of immunoglobulin replacement therapy.
c 5–95 percentile range for age-matched controls adopted from [7].
d 10–90 percentile range for age-matched controls adopted from [8].4. Results and discussion
To identify the underlying disease cause, we undertook whole
exome sequencing (WES) on the patient and both parents. A novel
heterozygous frameshift variant was detected in DOCK8 in the patient
and her mother. Sanger sequencing conﬁrmed a single-nucleotide du-
plication [c.6019dupT (p.Tyr2007Leufs*12)] within the conserved
DOCK homology region 2 (DHR2) domain of DOCK8, leading to a frame-
shift and premature stop-codon (Fig. 1, A and C, and Supplementary
Table 1]. As autosomal recessive mutations in DOCK8 cause combined
immunodeﬁciency, we screened for further variants in DOCK8. Analysis
of single nucleotide polymorphisms (SNPs) across DOCK8 in the trio re-
vealed apparent loss of paternal contribution of two SNPs in a 5′ region
of the gene (Supplementary Table 1), indicating the possibility of a
paternally inherited deletion. Array comparative genomic hybridization
analysis conﬁrmed a large deletion encompassing exons 1–14 of DOCK8
in the patient and her father (approx. 140 kb deletion of 9p24.3, base
pair 204,193 to 343,954) (Fig. 1, B and C). This novel compound hetero-
zygous mutation in DOCK8was the only disease-causing variant identi-
ﬁed in the patient (Supplementary Tables 2–4).
The deletion in DOCK8 is predicted to result in the absence of any
protein expression since the deletion includes the start codon. The
frameshiftmutation is predicted to result in the production of a truncat-
ed protein lacking 81 amino acids (~11 kDa). Indeed, patient EBV cells
expressed low amounts of a truncated DOCK8 protein, but not the
full-length protein (Fig. 1D). We hypothesized that this truncated
DOCK8 protein has hypomorphic function accounting for the milder
clinical presentation of our patient.
Previous studies of DOCK8-deﬁcient patients report impaired T cell
proliferation [1,2]. At the age of ten years, both CD4+ and CD8+ patient
T cells did not proliferate in response tomitogen (PHA) stimulation (Fig.
2A), consistent with an inability of the truncated DOCK8 protein to
transmit proliferative signals. Interestingly, when studying T cell prolif-
eration at the time ofWES (four years later), proliferation of both CD4+
and CD8+ patient T cells was present, although reduced compared to a
healthy control (Fig. 2B). We hypothesized that this difference in T cell
proliferation could be explained by somatic reversion of DOCK8. Indeed,
Sanger sequencing of DOCK8 cDNA of T cells and subsequent peak
height quantiﬁcation revealed that two thirds of all DOCK8 transcripts
are wild-type (Fig. 2C), showing somatic reversion of DOCK8 as previ-
ously described [3]. Somatic reversion ofDOCK8 in T cellswas conﬁrmed
by pyrosequencing ofDOCK8 (Fig. 2D). Therefore improved T cell prolif-
eration over time is likely to be due to somatic reversion ofDOCK8 in pa-
tient T cells.
The frequency of somatic reversion in B cells was half compared to
the DOCK8 reversion in T cells (Fig. 2D) indicating a higher proportion
of B cells expressing only the truncated DOCK8. Interestingly, patient
CD19+ B cells immortalized with EBV expressed only mutated DOCK8
transcripts (Fig. 2E) suggesting selective outgrowth of cells that did
not undergo somatic reversion. As migration of DOCK8-deﬁcient B
cells has previously been shown to be impaired [5], we investigated
the functionality of the truncated DOCK8 protein in a transwell assay
using the patient EBV B cells expressing only the truncated version of
DOCK8. Migration of patient EBV B cells was comparable to the EBV B
cell lines of healthy controls and signiﬁcantly better than that of EBV B
cells of a patient with complete loss-of-function mutation in DOCK8
(DOCK8null) (Fig. 2F). This shows thatmigrationwas not signiﬁcantly af-
fected by the truncation of the DOCK8 protein.
DOCK8 is a large protein with at least two described functional do-
mains, the N-terminal DOCK homology region (DHR) 1 domain and
the C-terminal DHR2 domain. There is only little data available on
which downstream cellular functions are mediated by each domain.
Our data showing normal migration of patient EBV cells expressing a
truncated DOCK8 protein in which the C-terminal DHR2 domain is
disrupted suggest that this domain is dispensable for lymphocyte mi-
gration. In line, Ham et al. [6] showed that the N-terminal region of
Fig. 1. A novel compound heterozygous mutation in DOCK8 results in expression of a truncated DOCK8 protein. (A) Sanger sequencing results for the single nucleotide duplication,
c.6019dupT, p.(Tyr2007Leufs*12). The upper panel illustrates a normal control trace and the lower panel shows the presence of the mutation; the duplicated T nucleotide is indicated
by the arrow. (B) Results of array comparative genomic hybridization illustrating the about 140 kb deletion in 9p24.3 (204,193–343,954). The deletion encompasses exons 1–14 of
DOCK8. (C) Graphic depicting thewild-type DOCK8 protein structure and the outcome of the single-nucleotide insertion on the maternal allele and the deletion in DOCK8 on the paternal
allele on DOCK8 protein expression (DOCK8 transcript reference is ENST00000453981). (D) DOCK8 protein expression in EBV-transformed B cells of a healthy control (7.5 μg protein
lysate) and the patient (30 μg protein lysate). Actin was used as loading control.
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for Wiskott–Aldrich syndrome protein (WASp), a protein involved in
actin cytoskeleton remodeling and migration.
The C-terminal DHR2 domain of DOCK8 exhibits the guanine nucle-
otide exchange in the small GTPase cell division control protein 42
homolog (CDC42). To our knowledge it is not yet clear which cellular
functions are modulated by signaling events initiated by the DOCK8-
mediated guanine nucleotide exchange. Absent T cell proliferation
when the patient presented initially in clinic, presumably before somat-
ic reversion took place, suggests that lymphocyte proliferation is likely
modulated by the guanine nucleotide exchange function in the DHR2
domain. Further in-depth characterization of truncated DOCK8 proteins
will provide a valuable tool for gaining a better understanding of the
function of DOCK8 in immune regulation and genotype–phenotype cor-
relations in various patients with DOCK8 deﬁciencies.
Currently, curative hematopoietic stem cell transplantation (HSCT)
is the deﬁnitive treatment for DOCK8 deﬁciency. Without HSCT, infec-
tions and an increased risk of developing malignancies due to impaired
clearance of oncogenic viruses are life-threatening complications asso-
ciated with DOCK8 deﬁciency. HSCT is expected to prevent both; how-
ever there is no data available on the development of malignancies
post-HSCT. In our patient, expression of truncated, partially functional
DOCK8 in combination with somatic reversion in T cells is sufﬁcient to
maintain antiviral immunity, as shown by the absence of severe viral in-
fections. Therefore, the risk versus beneﬁt of HSCT is unclear in patients
with less severe disease and demands careful consideration.5. Conclusion
Here we reported a patient with atypical DOCK8 deﬁciency charac-
terized by a much milder phenotype of the immunodeﬁciency
compared to classical DOCK8 deﬁciency which further broadens the
spectrum of DOCK8 associated diseases. As suggested by normal patient
EBV B cell migration and initially absent T cell proliferation in addition
to somatic reversion of DOCK8 predominantly in T cells, this relatively
mild phenotype is the result of hypomorphic DOCK8 function and
somatic reversion.
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Fig. 2. Improvement of T cell proliferation over time, somatic reversion of DOCK8 in T cells and hypomorphic function of the truncated DOCK8 protein. Proliferation of PHA-stimulated,
CFSE-labeled PBMCs of the patient at (A) 10 and (B) 15 years of age, and a healthy control. Depicted are percentages of CFSElow cells gated on CD3+ CD4+ or CD4− or CD8+ T cells.
(C) Sanger sequence trace showing somatic reversion of the single nucleotide duplication (c.6019dupT) resulting in expression of about 60% wild-type DOCK8 transcripts in the patient's
CD3+T cells. (D) “T”nucleotide phosphorescence ratios obtained bypyrosequencingDOCK8of primary CD3+CD4+ and CD3+CD8+T cells, primaryCD19+B cells and the EBVB cell line of
the patient. (T/± 1 or 2) depicts the signal ratio of c.6018-19T to nucleotides 1 and 2 positions up and downstream. The PCR templates and pyrosequencing reactions were performed
in triplicate. Each symbol represents the mean of the three ratio measurements at respective nucleotide positions. The bar represents the mean “T” nucleotide phosphorescence ratio
of all 4 different nucleotide ratios in indicated cell populations. (E) Sanger sequence trace showing expression of solelymutatedDOCK8 transcripts inEBV-transformedB cells of the patient.
The duplicated T-nucleotide is indicated by the arrow and #. (F) Migration of EBV-transformed B cells of 5 different healthy controls (each symbol represents the mean of 3 independent
experiments for each of the healthy control samples), the patient and a patient with a complete loss-of-function mutation in DOCK8 (DOCK8null). The bar of the healthy control samples
represents themean of themean of each of the 5 healthy control samples. The bar for each of the patient samples represents mean and standard deviation of 3 independent experiments
for each sample.
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